CSL eyeing acquisition candidate in Vifor Pharma
An Australian media has indicated that CSL is in talks to acquire Swiss Vifor Pharma, a competitor to Pharmacosmos, which is based in Denmark.
by MARKETWIRE, translated by daniel pedersen
The Swiss specialty pharmaceuticals company, Vifor Pharma, is up 15.6 percent at CHF 120 (USD 130,4) following news that Australian CSL wants to take over the Swiss firm, writes Bloomberg News, citing Australian Financial Reviews.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck Foundation portfolio company acquired for USD 230m
For subscribers
Vifor Pharma gets new CEO
For subscribers
